Claro Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Claro Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-192	Closed	-$10K	–	540
2018 Q4	$10K	Buy	+192	New	+$9.79K	0.01%	676

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claro Advisors's IONS Position: Q1 2019 in Review

Claro Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2019, closing a stake of 192 shares — an estimated $10K sold.

Claro Advisors first reported a position in IONS in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 392 funds tracked by Wall St. Rank hold IONS as of Q1 2019.

Claro Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 192 Ionis Pharmaceuticals shares in Q1 2019, an estimated $10K.
Claro Advisors first reported a position in Ionis Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claro Advisors's Ionis Pharmaceuticals position peaked at $10K in Q4 2018.
392 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.